TrialClinical pharmacokinetics2022

Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.

James D Chalmers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.